- QULIPTA is the first and only oral calcitonin gene-related
peptide (CGRP) receptor antagonist (gepant) specifically developed
for the preventive treatment of episodic migraine.
- AbbVie is the only pharmaceutical company to offer three
treatments across the full spectrum of migraine to help patients
living with this debilitating disease.
MONTRÉAL, Jan. 9, 2023
/CNW Telbec/ - AbbVie (NYSE: ABBV) announced today that
Health Canada has approved QULIPTA (atogepant) for the prevention
of episodic migraine (< 15 migraine days per month) in
adults.1 QULIPTA, the first and only oral
calcitonin gene-related peptide (CGRP) receptor antagonist (gepant)
preventive treatment, marks the latest innovation in AbbVie's
migraine portfolio to support Canadians impacted by migraine.
"Migraine is one of the leading causes of disability in
Canada and impacts a person's
ability to function and perform their daily routines," says Dr.
Elizabeth Leroux, Founder and Chair,
Migraine Canada. "People with migraine face incredible challenges
managing a debilitating neurological condition that others cannot
see or truly understand. Migraine Canada welcomes the approval of QULIPTA for
Canadians who will now have an opportunity to experience a new
treatment that will help prevent and manage episodic migraine
appropriately and take control of their migraine attacks before
they even start."
The approval is supported by data from a robust clinical program
evaluating the efficacy, safety and tolerability of QULIPTA in
nearly 2,000 patients who experienced 4 to 14 migraine days per
month. QULIPTA demonstrated statistically significant, clinically
meaningful, rapid and continuous reductions in mean monthly
migraine days among adults with episodic migraine compared to
placebo across the 12-week treatment period with significant
reductions seen in weeks 1-4. 1
"AbbVie is committed to bringing new innovative treatments to
address the needs of Canadians living with migraine," says
Tracey Ramsay, Vice President and
General Manager, AbbVie Canada. "With the approval of QULIPTA for
the preventive treatment of episodic migraine, AbbVie has expanded
on our support to those living with migraine given the legacy of
BOTOX® for the treatment of chronic migraine, and
recently approved UBRELVY® for acute treatment of
migraine. AbbVie is proud to partner with the migraine community to
advance treatment and care for people living with this neurological
disease."
About Migraine
Migraine is a complex neurological disease with recurrent
attacks that lasts 4-72 hours. It can be defined by symptoms such
as moderate to severe pain intensity, nausea, vomiting, photophobia
and phonophobia.2 An estimated 2.7 million Canadians are
reported diagnosed with migraine, however the number of people
living with migraine is much higher.3 Episodic migraine
is characterized as having less than 15 headache days per month,
while 15 headache days or more per month, is considered chronic.
4
About QULIPTA
(atogepant)
QULIPTA (atogepant) is the first and only oral calcitonin
gene-related peptide (CGRP) receptor antagonist (gepant)
specifically developed for the preventive treatment of episodic
migraine. QULIPTA is an orally administered, small molecule,
selective calcitonin gene-related peptide (CGRP) receptor
antagonist that blocks the binding of the CGRP to its receptor.
CGRP is a neuropeptide that may play a role in migraine
pathophysiology.1
For important safety information, please consult the QULIPTA™
Product Monograph at www.abbvie.ca.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.ca. Follow AbbVie Canada on Twitter,
on Instagram or find us on LinkedIn.
For more information on AbbVie's complete migraine portfolio,
please visit www.abbvie.ca.
|
______________________________
|
|
1
|
AbbVie Canada. QULIPTA
Product Monograph. December 2022.
|
|
2
|
Headache Classification
Committee of the International Headache Society (IHS) The
International Classification of Headache Disorders, 3rd edition.
Cephalalgia. 2018;38(1):1-211. Accessed April 2022.
|
|
3
|
Ramage-Morin P., &
Gilmour, H. (2014). Prevalence of migraine in the Canadian
household population. Health Reports, 25(6): 10-16.
https://www150.statcan.gc.ca/n1/en/pub/82-003-x/2014006/article/14033-eng.pdf?st=CSyp19VF.
Accessed April 2022.
|
|
4
|
Migraine Canada. The
Migraine Family: categories and groups. Retrieved from
https://migrainecanada.org/posts/the-migraine-tree/roots/migraine-categories/the-migraine-family-categories-and-groups/.
Accessed April 2022.
|
SOURCE AbbVie Canada